|
Monday, June 6, 2011
-
Phase I study conducted at two premier cancer research facilities in Texas
-
$3.5 million convertible debt offering closed
SAN ANTONIO, Texas – Azaya Therapeutics, Inc. presented data from its ongoing Phase I study of ATI-1123 today at the annual meeting of the American Society of Clinical Oncology held in Chicago, IL.
|
|
Read more...
|